The study evaluated 2,248 patients who underwent hip or knee arthroplasty and received a standard multimodal regimen including periarticular injections. Half of the patients received PAI with bupivacaine HCl with or without ketorolac and morphine, while the other half received PAI with EXPAREL.
The study found that EXPAREL patients had pain scores of 1.98 whereas patients in the other group had scores of 2.43. Around 57 percent of EXPAREL patients reported no pain for the hip procedure as compared to 43.4 percent of patients in the standard group. There was a similar difference among knee procedure patients. Additionally, the study found that use of EXPAREL resulted in cost savings of $1,246 per patient.
EXPAREL is currently indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia.
More articles on devices:
LDR shares dip 5.2% — 6 quick facts
Spine device stock report: 5 key companies — March 26, 2015
10 things to know about SpineGuard’s 2014 financial report
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
